Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $334,290.70 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 3,919 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total value of $334,290.70. Following the completion of the transaction, the chief operating officer owned 73,810 shares in the company, valued at $6,295,993. This trade represents a 5.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $83.49 on Friday. The stock has a fifty day moving average price of $78.80 and a 200 day moving average price of $66.80. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The company has a market cap of $6.82 billion, a PE ratio of -22.69 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.88) EPS. Analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KYMR. Baker BROS. Advisors LP lifted its stake in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the last quarter. Finally, BVF Inc. IL increased its position in Kymera Therapeutics by 6.6% during the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after purchasing an additional 340,909 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on KYMR. JPMorgan Chase & Co. lifted their price target on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Citigroup upped their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Stephens upped their target price on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Morgan Stanley reiterated an “overweight” rating and set a $123.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Finally, Wells Fargo & Company lifted their price objective on Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near?term loss forecasts (small EPS improvements across Q1–Q4 2026), kept a “Buy” rating and reiterated a $134 price target — this reinforces constructive analyst sentiment and supports buying interest. Read More.
• Positive Sentiment: UBS and several peers have raised price targets (UBS to $128, Barclays/Oppenheimer/Mizuho also higher), signaling consensus analyst optimism around Kymera’s pipeline progress as a medium?term catalyst. Read More.
• Positive Sentiment: Another outlet reported a price?target bump to $100 — additional upward target revisions help underpin sentiment even as valuation remains tied to clinical milestones. Read More.
• Positive Sentiment: Coverage highlights a healthy cash runway (~$1.6B reported) and upcoming program milestones (KT?579 data in 2H26; KT?621 Phase 2b readouts in 2027) that are the primary value drivers for this clinical?stage biotech. Read More.
• Neutral Sentiment: Technical/contextual note — KYMR is trading above its 200?day moving average with elevated volatility (beta ~2.2); analyst average targets remain well above current levels, which can amplify momentum in either direction. Read More.
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M at ?$90), a material single?day disposal that can be perceived as profit?taking and may cap short?term upside. Read More.
• Negative Sentiment: Multiple senior insiders (CFO Bruce Jacobs, COO Jeremy Chadwick, Jared Gollob and others) disclosed sales across March 2–4 at roughly $85–$89, each trimming holdings by a few percent — repeated insider selling increases short?term supply and investor caution. Read More.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.